150 related articles for article (PubMed ID: 25972901)
1. Patterns of thyroid hormone levels in pediatric medullary thyroid carcinoma patients on vandetanib therapy.
Lodish M; Gkourogianni A; Bornstein E; Sinaii N; Fox E; Chuk M; Marcus L; Akshintala S; Balis F; Widemann B; Stratakis CA
Int J Pediatr Endocrinol; 2015; 2015(1):3. PubMed ID: 25972901
[TBL] [Abstract][Full Text] [Related]
2. Medullary thyroid carcinoma in children with multiple endocrine neoplasia types 2A and 2B.
Skinner MA; DeBenedetti MK; Moley JF; Norton JA; Wells SA
J Pediatr Surg; 1996 Jan; 31(1):177-81; discussion 181-2. PubMed ID: 8632274
[TBL] [Abstract][Full Text] [Related]
3. The different requirement of L-T4 therapy in congenital athyreosis compared with adult-acquired hypothyroidism suggests a persisting thyroid hormone resistance at the hypothalamic-pituitary level.
Bagattini B; Cosmo CD; Montanelli L; Piaggi P; Ciampi M; Agretti P; Marco GD; Vitti P; Tonacchera M
Eur J Endocrinol; 2014 Nov; 171(5):615-21. PubMed ID: 25305309
[TBL] [Abstract][Full Text] [Related]
4. Role of vandetanib in the management of medullary thyroid cancer.
Brassard M; Rondeau G
Biologics; 2012; 6():59-66. PubMed ID: 22500115
[TBL] [Abstract][Full Text] [Related]
5. Evaluating vandetanib in the treatment of medullary thyroid cancer: patient-reported outcomes.
Fallahi P; Ferrari SM; Elia G; Ragusa F; Paparo SR; Ruffilli I; Patrizio A; Materazzi G; Antonelli A
Cancer Manag Res; 2019; 11():7893-7907. PubMed ID: 31686907
[TBL] [Abstract][Full Text] [Related]
6. The Reality of Multiple Endocrine Neoplasia Type 2B Diagnosis: Awareness of Unique Physical Appearance Is Important.
Nagaoka R; Sugitani I; Sanada M; Jikuzono T; Okamura R; Igarashi T; Akasu H; Shimizu K
J Nippon Med Sch; 2018; 85(3):178-182. PubMed ID: 30135345
[TBL] [Abstract][Full Text] [Related]
7. Biochemical Markers Reflecting Thyroid Function in Athyreotic Patients on Levothyroxine Monotherapy.
Ito M; Miyauchi A; Hisakado M; Yoshioka W; Ide A; Kudo T; Nishihara E; Kihara M; Ito Y; Kobayashi K; Miya A; Fukata S; Nishikawa M; Nakamura H; Amino N
Thyroid; 2017 Apr; 27(4):484-490. PubMed ID: 28056660
[TBL] [Abstract][Full Text] [Related]
8. Preclinical characterization of tyrosine kinase inhibitor-based targeted therapies for neuroendocrine thyroid cancer.
Pozo K; Zahler S; Ishimatsu K; Carter AM; Telange R; Tan C; Wang S; Pfragner R; Fujimoto J; Grubbs EG; Takahashi M; Oltmann SC; Bibb JA
Oncotarget; 2018 Dec; 9(102):37662-37675. PubMed ID: 30701022
[TBL] [Abstract][Full Text] [Related]
9. Vandetanib successfully controls medullary thyroid cancer-related Cushing syndrome in an adolescent patient.
Nella AA; Lodish MB; Fox E; Balis FM; Quezado MM; Whitcomb PO; Derdak J; Kebebew E; Widemann BC; Stratakis CA
J Clin Endocrinol Metab; 2014 Sep; 99(9):3055-9. PubMed ID: 24617713
[TBL] [Abstract][Full Text] [Related]
10. Serum levels of carboxyterminal cross-linked telopeptide of type I collagen (ICTP) in the differential diagnosis of the syndromes of inappropriate secretion of TSH.
Persani L; Preziati D; Matthews CH; Sartorio A; Chatterjee VK; Beck-Peccoz P
Clin Endocrinol (Oxf); 1997 Aug; 47(2):207-14. PubMed ID: 9302396
[TBL] [Abstract][Full Text] [Related]
11. Differentiated thyroid cancer in two patients with resistance to thyroid hormone.
Paragliola RM; Lovicu RM; Locantore P; Senes P; Concolino P; Capoluongo E; Pontecorvi A; Corsello SM
Thyroid; 2011 Jul; 21(7):793-7. PubMed ID: 21649470
[TBL] [Abstract][Full Text] [Related]
12. Cushing Disease in a patient with Multiple Endocrine Neoplasia type 2B.
Kasturi K; Fernandes L; Quezado M; Eid M; Marcus L; Chittiboina P; Rappaport M; Stratakis CA; Widemann B; Lodish M
J Clin Transl Endocrinol Case Rep; 2017 Jun; 4():1-4. PubMed ID: 28435794
[TBL] [Abstract][Full Text] [Related]
13. Factors affecting suppression of endogenous thyrotropin secretion by thyroxine treatment: retrospective analysis in athyreotic and goitrous patients.
Bartalena L; Martino E; Pacchiarotti A; Grasso L; Aghini-Lombardi F; Buratti L; Bambini G; Breccia M; Pinchera A
J Clin Endocrinol Metab; 1987 Apr; 64(4):849-55. PubMed ID: 3818906
[TBL] [Abstract][Full Text] [Related]
14. Changes in TSH levels in athyreotic patients with differentiated thyroid cancer during levothyroxine therapy: influence on dose adjustments.
Grani G; Tumino D; Ramundo V; Ciotti L; Lomonaco C; Armillotta M; Falcone R; Lucia P; Maranghi M; Filetti S; Durante C
J Endocrinol Invest; 2019 Dec; 42(12):1485-1490. PubMed ID: 31203497
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of Vandetanib in Treating Locally Advanced or Metastatic Medullary Thyroid Carcinoma According to RECIST Criteria: A Systematic Review and Meta-Analysis.
Trimboli P; Castellana M; Virili C; Giorgino F; Giovanella L
Front Endocrinol (Lausanne); 2018; 9():224. PubMed ID: 29774010
[TBL] [Abstract][Full Text] [Related]
16. Long-term follow-up and safety of vandetanib for advanced medullary thyroid cancer.
Ramos HE; Hecht F; Berdelou A; Borget I; Leboulleux S; Baudin E; Schlumberger M
Endocrine; 2021 Feb; 71(2):434-442. PubMed ID: 32691271
[TBL] [Abstract][Full Text] [Related]
17. The hypothalamic-pituitary-thyroid negative feedback control axis in children with treated congenital hypothyroidism.
Fisher DA; Schoen EJ; La Franchi S; Mandel SH; Nelson JC; Carlton EI; Goshi JH
J Clin Endocrinol Metab; 2000 Aug; 85(8):2722-7. PubMed ID: 10946871
[TBL] [Abstract][Full Text] [Related]
18. Medullary thyroid carcinoma as part of a multiple endocrine neoplasia type 2B syndrome: influence of the stage on the clinical course.
Leboulleux S; Travagli JP; Caillou B; Laplanche A; Bidart JM; Schlumberger M; Baudin E
Cancer; 2002 Jan; 94(1):44-50. PubMed ID: 11815959
[TBL] [Abstract][Full Text] [Related]
19. Triiodothyronine levels in athyreotic individuals during levothyroxine therapy.
Jonklaas J; Davidson B; Bhagat S; Soldin SJ
JAMA; 2008 Feb; 299(7):769-77. PubMed ID: 18285588
[TBL] [Abstract][Full Text] [Related]
20. Prevalence of sporadic medullary thyroid carcinoma: the importance of routine measurement of serum calcitonin in the diagnostic evaluation of thyroid nodules.
Rieu M; Lame MC; Richard A; Lissak B; Sambort B; Vuong-Ngoc P; Berrod JL; Fombeur JP
Clin Endocrinol (Oxf); 1995 May; 42(5):453-60. PubMed ID: 7621562
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
